Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629499 · ClinicalTrials.gov registry record · Phase 2
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00629499 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 63 participants.
The verdict
NCT00629499, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study. Approximately 50 patients are planned to be enrolled in this study.
Interventions
- DRUG Trastuzumab
- DRUG Cyclophosphamide
- DRUG nab paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00629499
The ClinicalTrials.gov registry entry for NCT00629499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT00629499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00629499 about?
NCT00629499 is a clinical study titled "Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer". This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study. Approximately 50 patients are planned to be enrolled in this study.
What is the current status of trial NCT00629499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2008-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00629499?
The interventions under investigation include: Trastuzumab (DRUG), Cyclophosphamide (DRUG), nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00629499?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.